![Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health](https://publichealth.jhu.edu/sites/default/files/styles/social_image/public/2023-02/bivalent-vaccine-g1422104879.jpg?itok=mgeH3XVw)
Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health
![Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN](https://dynaimage.cdn.cnn.com/cnn/c_fill,g_auto,w_1200,h_675,ar_16:9/https%3A%2F%2Fcdn.cnn.com%2Fcnnnext%2Fdam%2Fassets%2F221024193034-covid-19-booster-090922.jpg)
Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN
Moderna su LinkedIn: Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214… | 13 commenti
![Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore](https://www.sanita24.ilsole24ore.com/images2014/Editrice/ILSOLE24ORE/QUOTIDIANO_SANITA/2022/09/15/Quotidiano%20Sanita/ImmaginiWeb/Clipboard-0016.png)
Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore
![Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice | Science Immunology Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice | Science Immunology](https://www.science.org/cms/10.1126/sciimmunol.ade9888/asset/48a118e9-748c-4457-aef2-878a8451c21c/assets/images/large/sciimmunol.ade9888-f3.jpg)
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice | Science Immunology
![Omicron BA.4/BA.5-adapted bivalent vaccine generates higher antibody response - Hospital Pharmacy EuropeHospital Pharmacy Europe Omicron BA.4/BA.5-adapted bivalent vaccine generates higher antibody response - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2022/10/Omicron-BA.4-BA.5-adapted-bivalent-vaccine-generates-higher-antibody-response.jpg)
Omicron BA.4/BA.5-adapted bivalent vaccine generates higher antibody response - Hospital Pharmacy EuropeHospital Pharmacy Europe
CDC on X: "The updated #COVID19 booster can both help restore protection that has waned since the previous vaccination and provide broader protection against newer BA.4 and BA.5 Omicron subvariants. Learn more:
![ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine | Australian Government Department of Health and Aged Care ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/2022-11/atagi-recommendations-on-use-of-the-pfizer-bivalent-original-omicron-ba-1-covid-19-vaccine.png)
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine | Australian Government Department of Health and Aged Care
![News - CHMP Recommends Authorisation of Comirnaty Variant (BioNTech/Pfizer) Adapted to Omicron BA.4/BA.5 As Booster Vaccination for Children Aged 5 to 11 Years - Paul-Ehrlich-Institut News - CHMP Recommends Authorisation of Comirnaty Variant (BioNTech/Pfizer) Adapted to Omicron BA.4/BA.5 As Booster Vaccination for Children Aged 5 to 11 Years - Paul-Ehrlich-Institut](https://www.pei.de/SharedDocs/Bilder/EN/newsroom-en/hp-news-pm/comirnaty-booster-opinion-adolescents.jpg?__blob=thumbnail&v=4)